State Drug Administration investigates Hisense's color ultrasound industry expansion, encourages industry innovation and development

On June 3, Xu Jinghe, deputy director of the State Drug Administration, investigated Hisense, focusing on Hisense's strategic layout, technological innovation and industrial expansion in the field of medical imaging.

On June 3, Xu Jinghe, deputy director of the State Drug Administration, investigated Hisense, focusing on Hisense's strategic layout, technological innovation and industrial expansion in the field of medical imaging. Chairman Zhou Houjian, Senior Vice President Li Fei and other group leaders received and reported.

图片11.png 


Hisense ultrasound development took 9 years, last October the first color ultrasound product HD60 officially launched, the product is the first color ultrasound products with full independent intellectual property rights in Shandong Province, in software, hardware, algorithms and other aspects of independent mastery of core technology, fill the industrial gaps in the field of color ultrasound medical equipment in Shandong Province, to create high-end medical imaging industry chain, to promote the localization process of high-end medical imaging industry.

 图片12.png

 

The ultrasonic front-end hardware design is complex and technically difficult. These circuit boards are designed by Hisense R&D engineers independently, using 14-layer high-density PCB alignment design, with the thinnest alignment width of about 0.1mm, containing a large number of core technologies, a lot of efforts and wisdom of ultrasonic R&D engineers to support the system to achieve high-speed real-time acquisition and real-time processing of 128 faint signals. In addition to the hardware, the entire system software has about 1.3 million lines of code, which are written line by line by Hisense R & D engineers.

 

At present, Hisense ultrasound products have declared 53 national invention patents (12 have been authorized), been approved as the first set of products in Shandong Province, selected as a major science and technology innovation project in Shandong Province, and entered the list of "Science and Technology China Pioneer Technology" in 2020 by China Association for Science and Technology.

 

Today, the product has been applied in more than 20 tertiary hospitals, and the application cases have exceeded 30,000 cases.